Applications of 4-(2-Hydroxyethyl)-Piperazin-1-Carboxylic Acid Ethyl Ester in Industrial Manufacturing

4-(2-Hydroxyethyl)-Piperazin-1-Carboxylic Acid Ethyl Ester serves as a key intermediate in multiple industrial sectors. Its molecular properties support controlled buffering, selective chemical modification, and precise molecular integration. The following sections detail specific downstream applications and technical details based on global manufacturing standards.

1. Active Pharmaceutical Ingredient (API) Synthesis for Oncology Drugs

Leading pharmaceutical manufacturers leverage this ester during the development of antineoplastic APIs involving heterocyclic frameworks. Its role as a masked piperazine unit enables stepwise functionalization under mild conditions, supporting the synthesis of cytostatic agents. The esterification improves throughput in coupling reactions, crucial for batch and continuous-flow GMP production.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP-NF Monographs (process-relevant for intermediates)
• European Pharmacopoeia General Monographs
• FDA 21 CFR Part 211 Process Controls

Typical usage ratio

• 1-8 mol% with respect to core pharmaceutical intermediate, adjusted per desired target motif and process route.
• Ratio tuning based on solvent compatibility, reaction selectivity, and trace residual limits.

Downstream process integration

• Used in pre-activation stages for ring closure or heterocycle extension.
• Integrated into amidation or urea/thiourea assembly steps within multipurpose reactors.
• Undergoes controlled deprotection in penultimate synthetic steps before final API crystallization.

Final product types

• Oral and injectable oncology drug APIs (e.g., piperazine-derivative cytostatics)
• Precursor batches for small molecule targeted therapies
• Peptide-heterocycle hybrids for clinical development

2. Biotech Buffer System Manufacturing

Industrial biotech facilities adopt this compound as a secondary buffer component in critical biological assays and large-scale fermentation. Its pKa near neutrality and low background reactivity allow precise pH control in protein purification, cell lysis, and viral vector preparation. Plant operators prefer it for applications demanding low metal ion chelation and minimal enzyme inhibition.

Industry compliance standards

• ISO 13485 (biotechnology and life sciences QC)
• USP <1046> Cell and Gene Therapy Products
• European GMO and ATMP regulatory guidelines
• GMP cleanroom standards (ISO 14644-1)

Typical usage ratio

• 5-30 mM in fermentation broths, lysis buffers, and chromatography media formulations.
• Adjusted according to target pH, protein stability profile, and process temperature.

Downstream process integration

• Introduced during buffer preparation in mixing tanks prior to bioreactor charging.
• Supports pH maintenance during cell disruption and protein elution in chromatography skids.
• Compatible with single-use process components and continuous DSP modules.

Final product types

• Purified monoclonal antibodies and therapeutic proteins
• Gene therapy viral vectors and viral vaccines
• Cell bank preservation and passaging reagents

3. Specialty Resin Synthesis for Epoxy Formulations

Manufacturers of high-performance epoxy resins utilize this piperazine ester to introduce chain flexibility and site-selective crosslinking in electronic encapsulants, adhesives, and coatings. Its hydroxyethyl group enables further functionalization, while the protected amine facilitates staged curing. This approach ensures superior dielectric properties and minimal extractables in electronics and aerospace-grade applications.

Industry compliance standards

• REACH (EC) 1907/2006 Chemical Safety
• RoHS Directive (EU) 2015/863 for electronics-related materials
• UL 94 Flammability Certification for Plastics
• IPC-4101 Epoxy Glass Fabric Laminates (for PCB use)

Typical usage ratio

• 0.5-4% by weight relative to total epoxy monomer mass
• Modified based on desired crosslink density, flexibility, and heat distortion benchmarks

Downstream process integration

• Blended at the prepolymer stage with diglycidyl ether and hardeners
• Post-functionalized prior to curing for compatibility with silica, fillers, or fiber reinforcements
• Applicable for potting compounds, encapsulating resins, and conformal coatings

Final product types

• PCB encapsulants with enhanced thermal cycling resistance
• Optoelectronic sealing adhesives
• Protective coatings for critical aerospace components

4. Polymer Modification in Advanced Coatings

This raw material enables formulators to modify polyurethane dispersions and acrylic coatings, imparting improved film formation and tailored hydrophilicity. Its structure facilitates covalent integration into polymer backbones via transesterification or amidation, resulting in coatings with defined flexibility, abrasion resistance, and chemical barrier properties for automotive, marine, and architectural sectors.

Industry compliance standards

• ASTM D16 Terminology for Paint, Related Coatings, and Application Techniques
• EN 13523-10 Determination of Resistance to Chemical Spot Test
• ISO 12944 Corrosion Protection of Steel Structures by Protective Paint Systems
• Directive 2004/42/EC (VOC Content in Coatings)

Typical usage ratio

• 0.8-3.5 phr (parts per hundred resin) for polyurethane dispersions
• Adjusted after test panels according to gloss, mechanical, and weathering outcomes

Downstream process integration

• Introduced during polyol preprocessing to control chain termination and side group functionality
• Functionalization step precedes pigment dispersion and letdown blending
• Integrated in batch reactors or inline dosing in advanced coating lines

Final product types

• High-durability clearcoats for automotive OEM lines
• Marine anti-corrosive paints
• Self-priming wall and flooring finishes

5. Diagnostic Reagent Preparation in Clinical Chemistry

IVD manufacturers and clinical diagnostic kit providers incorporate this ester into buffer and stabilizer formulations, ensuring accurate pH control and minimal interference with enzyme assays. The compound’s low UV absorbance facilitates photometric diagnostics, while its low toxicity profile supports regulatory acceptance in high-throughput automated analyzers.

Industry compliance standards

• ISO 13485:2016 (Medical Device Quality Management)
• 21 CFR Part 820 (Quality System Regulation for IVDs)
• CLSI C31-A2 (Preparation and Testing of Clinical Buffer Solutions)
• IVDR (EU) 2017/746 (In Vitro Diagnostic Regulation)

Typical usage ratio

• 5-25 mM in working buffer concentrates and calibrators
• Adjusted based on assay protocol, matrix interference profiles, and instrument compatibility

Downstream process integration

• Dosed in large-scale blending systems during primary buffer concentrate manufacturing
• Filtered through 0.22 µm systems before aseptic filling
• Compatible with lyophilization for extended shelf life

Final product types

• Enzyme-linked immunoassay kit buffers
• Routine clinical chemistry analyzer reagents
• Stabilization agents for point-of-care diagnostic cartridges